Expression and Endocytosis of Lysosomal Aspartylglucosaminidase in Mouse Primary Neurons
Authors:
Open Access
- 1 October 1998
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 18 (19) , 7750-7756
Abstract
Aspartylglucosaminuria (AGU) is a neurodegenerative lysosomal storage disease that is caused by mutations in the gene encoding for a soluble hydrolase, aspartylglucosaminidase (AGA). In this study, we have used our recently developed mouse model for AGU and analyzed processing, intracellular localization, and endocytosis of recombinant AGA in telencephalic AGU mouse neuronsin vitro. The processing steps of AGA were found to be similar to the peripheral cells, but both the accumulation of the inactive precursor molecule and delayed lysosomal processing of the enzyme were detected. AGA was distributed to the cell soma and neuronal processes but was not found in the nerve terminals. Endocytotic capability of cultured telencephalic neurons was comparable to that of fibroblasts, and endocytosis of AGA was blocked by free mannose-6-phosphate (M6P), indicating that uptake of the enzyme was mediated by M6P receptors (M6PRs). Uptake of extracellular AGA was also studied in the tumor-derived cell lines rat pheochromocytoma (PC12) and mouse neuroblastoma cells (N18), which both endocytosed AGA poorly as compared with cultured primary neurons. Expression of cation-independent M6PRs (CI-M6PRs) in different cell lines correlated well with the endocytotic capability of these cells. Although a punctate expression pattern of CI-M6PRs was found in fibroblasts and cultured primary neurons, the expression was beyond the detection limit in PC12 and N18 cells. This indicates that PC12 and N18 are not feasible cell lines to describe neuronal uptake of mannose-6-phosphate-tagged proteins. Thisin vitrodata will form an important basis for the brain-targeted therapy of AGU.Keywords
This publication has 39 references indexed in Scilit:
- Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouseGene Therapy, 1998
- Correction of Deficient Enzyme Activity in a Lysosomal Storage Disease, Aspartylglucosaminuria, by Enzyme Replacement and Retroviral Gene TransferHuman Gene Therapy, 1995
- Intracellular Sorting of Aspartylglucosaminidase: The Role of N -Linked Oligosaccharides and Evidence of Man-6-P-Independent Lysosomal TargetingDNA and Cell Biology, 1995
- Immediate Interaction between the Nascent Subunits and Two Conserved Amino Acids Trp34 and Thr206 Are Needed for the Catalytic Activity of AspartylglucosaminidaseJournal of Biological Chemistry, 1995
- Dissection of the Molecular Consequences of a Double Mutation Causing a Human Lysosomal DiseaseDNA and Cell Biology, 1994
- In vitro mutagenesis helps to unravel the biological consequences of aspartylglucosaminuria mutationGenomics, 1991
- Receptor Binding, Endocytosis, and Mitogenesis of Insulin‐Like Growth Factors I and II in Fetal Rat Brain NeuronsJournal of Neurochemistry, 1991
- Receptors for insulin-like growth factors and insulin on murine fetal cortical brain cellsBiochemical and Biophysical Research Communications, 1986
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970
- ASPARTYLGLYCOSAMINURIAThe Lancet, 1968